Impact of HIV coadministered HIV drug or regiment on DAA exposure (AUC)
Data are given in percentages.
| ARV Agent | SMP | SOF | DCV | LDV/SOF | OBV/PTV/DSV/r | GZR/EBR | SOF/VEL | SOF/VEL/VOX | GLE/PIB | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LDV | SOF | OBV | PTV | DSV | /r | GZR | EBR | SOF | VEL | VOX | GLE | PIB | ||||
| NRTI | ||||||||||||||||
| ABC/3TC | — | — | — | ↔ | ↔ | ↔ | ↓16 | ↔ | — | — | — | — | — | — | — | |
| TDF | ↔ | ↔ | ↔ | ↔ | ↔ | — | — | — | — | ↓14 | ↔ | — | ↔ | ↔ | — | — |
| Protease inhibitor (boosted) | ||||||||||||||||
| ATV/r | — | — | ↓30 | — | — | ↔ | ↑216 | ↔ | ↑218 | ↑958 | ↑376 | — | — | ↑331 | — | — |
| DRV/r | ↑159 | ↑34 | ↓30 | ↑39 | ↑34 | ↔,a ↓27,b ↔c | ↑29,a ↓41,b ↓19c | ↔,a ↓27,b ↓28c | ↔,a ↑28,b ↑70c | ↑650 | ↑66 | — | — | — | ↑397 | ↔ |
| LPV/r | — | — | ↓42 | — | — | ↔ | ↑117 (↑87) | ↔ (↓46) | ↑105 (↑162) | ↑1186 | ↑271 | — | — | — | ↑338 | ↑146 |
| Entry/integrase inhibitor (unboosted) | ||||||||||||||||
| DTG | — | — | ↔ | — | — | ↔ | ↓16 | ↔ | ↓19 | ↔ | ↔ | ↔ | — | — | — | |
| RAL | ↔ | ↔ | — | ↔ | ↔ | — | — | — | — | ↔ | ↓19 | — | ↔ | — | — | — |
| Non-NRTI | ||||||||||||||||
| EFV | ↓71 | — | ↑37 | — | — | — | — | — | — | ↓83 | ↓54 | — | — | — | — | — |
| RPV | ↔ | ↔ | — | — | — | ↔ | ↑23 | ↔ | ↔ | ↔ | ↔ | — | ↔ | — | — | — |
| Pharmacokinetic enhancers (boosters) | ||||||||||||||||
| RTV | ↑618 | — | — | — | — | — | — | — | — | ↑103 | — | — | — | — | — | — |
| Full treatment regimens | ||||||||||||||||
| ATV + RTV + FTC/TDF | — | — | — | ↑96 | ↔ | — | — | — | — | — | — | ↔ | ↑142 | — | — | — |
| BIC/FTC/TAF | — | — | — | ↔ | ↔ | — | — | — | — | — | — | — | — | ↔ | — | — |
| DRV + RTV + FTC/TDF | — | — | — | ↔ | ↓27 | — | — | — | — | — | — | ↓28 | ↔ | ↑143 | — | — |
| DTG + FTC/TDF | — | — | — | ↔ | ↔ | — | — | — | — | — | — | — | — | — | — | — |
| EFV /FTC/TDF | — | ↔ | — | ↓34 | ↔ | — | — | — | — | — | — | ↔ | ↓53 | — | — | — |
| EVG/COBI/FTC/TAF | — | — | — | ↑79 | ↑47 | — | — | — | — | ↑436 | ↑118 | ↑37 | ↑50 | ↑171 | ↑105 | ↑57 |
| EVG/COBI/FTC/TDF | — | — | — | — | — | — | — | — | — | — | — | ↔ | ↔ | — | — | — |
| LPV/RTV + FTC/TDF | — | — | — | — | — | — | — | — | — | — | — | ↓29 | ↔ | — | — | — |
| RPV/FTC/TAF | — | — | — | — | — | — | — | — | — | — | — | — | — | ↔ | — | — |
| RPV/FTC/TDF | — | — | — | ↔ | ↔ | — | — | — | — | — | — | ↔ | ↔ | — | — | — |
BIC, bictegravir; DCV, daclatasvir; DSV, dasabuvir; EBR, elbasvir; GLE, glecaprevir; GZR, grazoprevir; LDV, ledipasvir; OBV, ombitasvir; PIB, pibrentasvir; PTV, paritaprevir; RTV or/r, ritonavir; SMP, simeprevir; SOF, sofosbuvir; VEL, velpatasvir; VOX, voxilaprevir. ↑: increase in exposure; ↓: decrease in exposure; ↔: no change; —: data not available.
↵a 800 mg DRV daily AM plus OBV/PTV/DSV/r AM versus 800 mg daily DRV AM plus 100 mg RTV daily AM.
↵b 600 mg DRV twice daily AM/PM plus OBV/PTV/DSV/r AM plus 100 mg RTV daily PM versus 600 mg DRV twice daily AM/PM plus 100 mg RTV twice daily AM/PM.
↵c OBV/PTV/DSV/r AM plus 800 mg DRV daily PM plus 100 mg RTV daily PM versus 800 mg DRV daily PM plus 100 mg RTV daily PM.